U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07725380) titled 'Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma' on July 21.
Brief Summary: This is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.
Study Start Date: July 15
Study Type: INTERVENTIONAL
Condition:
Sarcoma
Osteosarcoma
Intervention:
DRUG: Domatinostat
Tablet
DRUG: Sirolimus
Tablet
Recruitment Status: RECRUITING
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Disclaime...